2 May 2016 - No sighificant differences for moderate disease and no data for severe disease. ...
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...
2 May 2016 - Without subsidy, it costs about US $260,000 each year. ...
2 May 2016 - The sponsor with the most number of submissions on the agenda for the next PBAC meeting ...
2 May 2016 - The public consultation process is now open for two PBAC post-market reviews. ...
1 May 2016 - The May 2016 issue of the Schedule sees a number of new and revised listings. ...
1 May 2016 - The May 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of two new medicines. ...
29 April 2016 - Thousands of women will benefit from subsidised access to the breast cancer drug Tamoxifen which has been ...
29 April 2016 - A new breakthrough melanoma drug has been approved for use in New Zealand, but like its rival ...
29 April 2016 - Medicines Australia notes the release of the draft report from the Productivity Commission concerning Australia’s Intellectual Property ...
29 April 2016 - NICE is today recommending a new drug combination for melanoma that could extend life by six months. ...
29 April 2016 - The PBS and RPBS Section 85 date of processing and date of supply data has now been ...
29 April 2016 - Global pharmaceutical giants are boosting revenues by unnecessarily extending patents in Australia, which is also slowing access ...
28 April 2016 - Up to 30,000 Australians living with a slow-growing form of lymphoma could benefit from a new anti-cancer ...
28 April 2016 - The agenda for the July 2016 PBAC meeting is now available. ...